Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma insulin-like growth factor-I and chosen hormones in breast cancer pre-menopausal patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 25, Issue 1, 2000, Pages 67-72

  Kajdaniuk, Dariusz ^a   Marek, B ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTRADIOL; FLUOROURACIL; GROWTH HORMONE; HORMONE; HYDROCORTISONE; MELATONIN; METENKEPHALIN; METHOTREXATE; PROGESTERONE; PROLACTIN; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD LEVEL; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; PREMENOPAUSE; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ESTRADIOL; FEMALE; FLUOROURACIL; HUMANS; HYDROCORTISONE; INSULIN-LIKE GROWTH FACTOR I; MELATONIN; METHOTREXATE; MIDDLE AGED; PREMENOPAUSE; PROGESTERONE; PROLACTIN;

EID: 0034119717     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2000.00265.x     Document Type: Article

References (39)

1. 1. Daughaday WH. (1990) The possible autocrine/ paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology, 127, 1-4.
2. 2. Osborne CK, Arteaga CL. (1990) Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Research and Treatment, 15, 3-11.
3. 3. Lee AV, Hilsenbeck SG, Yee D. (1998) IGF system components as prognostic markers in breast cancer. Breast Cancer Research and Treatment, 47, 295-302.
4. 4. Kajdaniuk D, Marek B. (1999) Insulin-like growth factor-I (IGF-I) and neoplasms. Postepy Nauk Medycznych, 12, 34-38.
5. 5. Kajdaniuk D, Marek B, Swietochowska E, Buntner B, Matuszewska G. (1999) Insulin-like growth factor-I: pathophysiological and clinical aspects. Polski Merkuriusz Lekarski, 7, 205-207.
6. 6. Marek B, Buntner B, Borgiel-Marek H, Kos-Kudla B, Ostrowska Z, Swietochowska E. (1996) Insulin-like growth factors and their binding proteins in physiology and pathology. Polskie Archiwum Medycyny Wewnetrznej, 96, 290-296.
7. 7. Aaronson SA. (1991) Growth factors and cancer. Science, 254, 1146-1153.
8. 8. Macaulay VM. (1992) Insulin-like growth factors and cancer. British Journal of Cancer, 65, 311-320.
9. 9. Foekens JA, Portengen H, Janssen M, Klijn JGM. (1989) Insulin-like growth factor-I receptors and insulin-like growth factor-I activity in human primary breast cancer. Cancer, 63, 2139-2147.
10. 10. Peyrat JP, Bonneterre J, Hecquet B, et al. (1993) Plasma insulin-like growth factor-1 (IGF-1) concentration in human breast cancer. European Journal of Cancer, 29A, 492-497.
11. 11. Karey KP, Sirbasku DA. (1988) Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17beta-estradiol. Cancer Research, 48, 4083-4092.
12. 12. Dunn SE, Hardman RA, Kari FW, Barrett JC. (1997) Insulin-like growth factor-I (IGF-I) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Research, 57, 2687-2693.
13. 13. Pfeilschifter J, Scheidt-Nave C, Leidig-Bruckner G, et al. (1996) Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50-to 80-year-old men and women. Journal of Clinical Endocrinology and Metabolism, 81, 2534-2540.
14. 14. Baxter RC. (1993) Circulating binding proteins for the insulin like growth factors. Trends in Endocrinology and Metabolism, 4, 91-96.
15. 15. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS. (1998) Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology, 9, 570-573.
16. 16. Rubin R, Baserga R. (1995) Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Laboratory Investigation, 73, 311-331.
17. 17. Weber MM, Auernhammer CJ, Kiess W, Engelhardt D. (1997) Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. European Journal of Endocrinology, 136, 296-303.
18. 18. Gasparini G. (1995) Biological and clinical role of angiogenesis in breast cancer. Breast Cancer Research and Treatment, 36, 103-107.
19. 19. Jordan VC. (1993) Can all postmenopausal women with a diagnosis of breast cancer benefit from tamoxifen treatment. Reviews on Endocrine-Related Cancer, 43, 23-31.
20. 20. Huynh HT, Tetenes E, Wallace L, Pollak M. (1993) In vivo inhibition insulin-like growth factor 1 gene expression by tamoxifen. Cancer Research, 53, 1727-1730.
21. 21. Favoni RE, Cupis A, Perrotta A, et al. (1995) Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early-and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status. Journal of Cancer Research and Clinical Oncology, 121, 674-682.
22. 22. Topper YJ, Freeman CS. (1990) Multiple hormone interaction in the development biology of the mammary gland. Physiological Reviews, 60, 1049-1115.
23. 23. Yang XF, Beamer WG, Huynh H, Pollak M. (1996) Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Research, 56, 1509-1511.
24. 24. Barni S, Lissoni P, Brivio F, et al. (1994) Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin. Tumori, 80, 212-215.
25. 25. Selman PJ, Mol JA, Rutteman GR, Rijnberg A. (1994) Progestin treatment in the dog. Effects on growth hormone, insulin-like growth factor I and glucose homeostasis. European Journal of Endocrinology, 131, 413-421.
26. 26. Woll PJ. (1991) Neuropeptide growth factors and cancer. British Journal of Cancer, 63, 469-475.
27. 27. Cos S, Blask DE. (1994) Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. Journal of Pineal Research, 17, 25-32.
28. 28. Lissoni P, Barni S, Meregalli S, et al. (1995) Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. British Journal of Cancer, 71, 854-856.
29. 29. Kajdaniuk D, Marek B, Kos-Kudla B, Ciesielska-Kopacz N, Buntner B. (1999) Oncostatic effects of melatonin action - facts and hypotheses. Medical Science Monitor, 5, 350-356.
30. 30. Bruning PF, Van-Doorn J, Bonfrer JM, et al. (1995) Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. International Journal of Cancer, 62, 266-270.
31. 31. Hankinson SE, Willett WC, Colditz GA, et al. (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 351, 1393-1396.
32. 32. Cotterill AM, Mendel P, Holly JM, et al. (1996) The differential regulation of the circulating levels of the insulin-like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery. Clinical Endocrinology, 44, 91-100.
33. 33. Bonadonna G, Valagussa P, Moliterni M, Zambetti C, Brambilla C. (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. New England Journal of Medicine, 332, 901-906.
34. 34. Peyrat JP, Revillion F, Bonneterre J. (1998) Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy. British Journal of Cancer, 77, 1669-1671.
35. 35. Helle SI, Lonning PE. (1996) Insulin-like growth factors in breast cancer. Acta Oncologica, 35(Suppl. 5), 19-22.
36. 36. Pollak M, Constantino J, Polychronakos C, et al. (1990) Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. Journal of the National Cancer Institute, 82, 1693-1697.
37. 37. Torrisi R, Pensa F, Orengo MA, et al. (1993) The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Research, 53, 4769-4771.
38. 38. Anderson E, Ferguson J, Morten H, Shalet SM, Robinson EL, Howell A. (1993) Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. European Journal of Cancer, 29A, 209-217.
39. 39. Murgo AJ, Faith RE, et al. (1986) Enkephalins: mediators of stress-induced immunomodulation. In: Plotnikoff NP, Murgo AJ, Faith RE, Good R, eds. Enkephalins-Endorphins: Stress and the Immune System. New York: Plenum Press, 221-239.